Other Guidance Documents
Technical Assistance Bulletins
ASHP's professional policies contain varying levels of detail. Policy positions are short pronouncements on one aspect of practice. Statements express basic philosophy, and guidelines (including what were formerly called "technical assistance bulletins") offer programmatic advice. Therapeutic position statements are concise responses to specific therapeutic issues, and therapeutic guidelines are thorough, evidence-based recommendations on drug use.
Therapeutic Guidelines
ASHP's professional policies contain varying levels of detail. Policy positions are short pronouncements on one aspect of practice. Statements express basic philosophy, and guidelines (including what were formerly called "technical assistance bulletins") offer programmatic advice. Therapeutic position statements are concise responses to specific therapeutic issues, and therapeutic guidelines are thorough, evidence-based recommendations on drug use.
+ View Guidelines
- Antimicrobial Prophylaxis in Surgery [PDF]
- Clinical Practice Guidelines for Sustained Use of Neuromuscular Blockade in the Adult Critically III Patient (available to ASHP members/subscribers only)
- Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists [PDF]
Therapeutic Position Statements
ASHP's professional policies contain varying levels of detail. Policy positions are short pronouncements on one aspect of practice. Statements express basic philosophy, and guidelines (including what were formerly called "technical assistance bulletins") offer programmatic advice. Therapeutic position statements are concise responses to specific therapeutic issues, and therapeutic guidelines are thorough, evidence-based recommendations on drug use.
+ View Statements
- Cessation of Tobacco Use
- Institutional Use of 0.9% Sodium Chloride Injection to Maintain Patency of Peripheral Indwelling Intermittent Infusion Devices
- Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients
- Strategies for Identifying and Preventing Pneumococcal Resistance
- Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder
- Antithrombotic Therapy in Chronic Atrial Fibrillation (available to ASHP members/subscribers only)
Endorsed Documents
Professional policy developed by another organization that offers guidance on some aspect of pharmacy practice or medication use, as approved by the Board of Directors.
+ View Endorsed Documents
- CHEST Guideline: Antithrombotic therapy for VTE disease [PDF]
- ACC/AHA Task Force on Performance Measures Report: Concepts for Clinician-Patient Shared Accountability in Performance Measures [PDF]
- American Heart Association/American College of Cardiology Foundation Update on Secondary Prevention Lipid Performance Measures
- American Society of Parenteral and Enteral Nutrition (A.S.P.E.N.) Standards of Practice for Nutrition Support Pharmacists
- Antibiotic Resistance Statement from 25 National Health Organizations and the Centers for Disease Control and Prevention [PDF]
- ASHP-ACCP-SCCM-CPG-Critical Care Pharmacy Services: 2020 Update [PDF]
- Camden Coalition's Core Competencies for Front-line Complex Care Providers [PDF]
- Credentialing and Privileging of Pharmacists: A Resource Paper from the Council on Credentialing in Pharmacy (2014)–Council on Credentialing in Pharmacy) AJHP [PDF]
- Code of Ethics for Pharmacists (Reviewed 2012) American Pharmaceutical Association [PDF]
- Definitions of Pharmacy Residencies and Fellowships - Developed by an Ad Hoc Consortium of AACP, ACA, ACCP, APhA, ASCP, ASHP, NARD [PDF]
- Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting [PDF]
- Institute for Healthcare Improvement - No Place Like Home: Advancing the Safety of Care in the Home [PDF]
- Joint Commission of Pharmacy Practitioners Vision for Pharmacists’ Practice [PDF]
- Joint Statement of the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists on Inappropriate Ordering, Prescribing or Dispensing of Medications to Treat COVID-19 [PDF]
- Ketamine Use in Prehospital and Hospital Treatment of the Acute Trauma Patient: A Joint Position Statement - ACS-COT, ACEP, NASEMSO, NAEMSP, and NAEMT [PDF]
- Long-Range Vision for the Pharmacy Work Force in Hospitals and Health Systems (Updated in 2019) – ASHP
- National Coordinating Council for Medication Error Reporting and Prevention Recommendations: Statement Opposing the Criminalization of Errors in Healthcare
- National Patient Safety Foundation - RCA2: Improving Root Cause Analyses and Actions to Prevent Harm [PDF]
- Partnership for Health in Aging: Position Statement on Interdisciplinary Team Training in Geriatrics: An Essential Component of Quality Healthcare for Older Adults
- Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics (2025)
- Performance Measures for Adults with Heart Failure (2011) — ACCF/AHA/AMA-PCPI
- Pharmacists’ Patient Care Process – Joint Commission of Pharmacy Practitioners (2014) [PDF]
- Principles for COVID-19 Vaccine Distribution, Allocation, and Mass Immunization (2020) [PDF]
- Principles of a Sound Drug Formulary System (Reviewed 2011) – Endorsed by a Working Group of National Organizations Representing Healthcare [PDF]
- Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-Trace Element Products (2012) – A.S.P.E.N. Position Paper
- Recommendations for Training, Credentialing, and Documenting and Justifying Critical Care Pharmacy Services (2011) Task Force of ACCP, SCCM, ASHP [PDF]
- Report of the ASHP Opioid Task Force
- Society for Ambulatory Anesthesia: Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
- Society of Critical Care Medicine Opinion Paper: Outlining Recommendations for Training, Credentialing, Documenting and Justifying Critical Care Pharmacy Services [PDF]
- Society of Hospital Medicine: Making Inpatient Medication Reconciliation Patient Centered, Clinically Relevant, and Implementable: A Consensus Statement on Key Principles and Necessary First Steps [PDF]
- Optimizing the Electronic Health Record in the Parenteral Nutrition Workflow (2018) - ASHP, ASPEN, Academy of Nutrition and Dietetics [PDF]
Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines
CPIC guidelines are designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered. A key assumption underlying the CPIC guidelines is that clinical high-throughput and pre-emptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients’ genotypes available even if they have not explicitly ordered a test with a specific drug in mind. ASHP reviews and endorses select guidelines on an annual basis.
+ View Guidelines
- CPIC Guideline for Fluoropyrimidines and DPYD
- CPIC Guideline for Potent Volatile Anesthetic Agents and Succinylcholine and RYR1 and CACNA1S
- CPIC Guideline for Ondansetron and Tropisetron based on CYP2D6 genotype
- CPIC Guideline for NSAIDs based on CYP2C9 genotype
- CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
- CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
- CPIC Guideline for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
- CPIC Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
- CPIC Guideline for Cytochrome P450-2C19 Genotype and Clopidogrel Therapy
- CPIC Guideline for HLA-B Genotype and Abacavir Dosing
- CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
- CPIC Guideline for CYP3A5 genotype and Tacrolimus Dosing
- CPIC Guideline for Allopurinol and HLA-B
- CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing
- CPIC Guideline for Phenytoin and CYP2C9 and HLA-B
- CPIC Guideline for CYP2C19 and Voriconazole Therapy
- CPIC Guideline for CYP2D6 and Tamoxifen Therapy
- CPIC Guidelines for Ondansetron and Tropisetron based on CYP2D6 genotype
- CPIC Guideline for Aminoglycosides and MT-RNR1
- CPIC Guideline Proton Pump Inhibitors and CYP2C19
- CPIC® Guideline for G6PD
- CPIC® Guideline for HLA genotype and Use of Carbamazepine and Oxcarbazepine
- CPIC® Guideline for Efavirenz based on CYP2B6 genotype
- CPIC® Guideline for Atomoxetine based on CYP2D6 genotype
- CPIC® Guideline for Atazanavir and UGT1A1
- CPIC® Guideline for Beta-blockers and CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5
- CPIC® Guideline for Methadone based on CYP2B6 genotype